vaborbactam
Trade name: Vabomere
Approved
Aug 29, 2017
Vaborbactam (formerly RPX7009) is a new beta-lactamase inhibitor based on a cyclic boronic acid pharmacophore. Vaborbactam is a highly active beta-lactamase inhibitor that restores activity of meropenem and other beta-lactam antibiotics in beta-lactamase-producing bacteria, particularly KPC-producing CRE. Meropenem in combination with vaborbactam (VABOMERE) is indicated for the treatment of patients 18 years and older with complicated urinary tract infections including pyelonephritis caused by designated susceptible bacteria. The vaborbactam component of VABOMERE is a non-suicidal beta-lactamase inhibitor that protects meropenem from degradation by certain serine beta-lactamases such as Klebsiella pneumoniae carbapenemase (KPC). Vaborbactam does not have any antibacterial activity. Vaborbactam does not decrease the activity of meropenem against meropenem-susceptible organisms. — NCATS
Clinical trial activity
2 trials · 2 clinical orgs · 2 marketing orgs
Earliest trial started May 1, 2018 (NCT03564158)
Timeline
2010s
- Aug 29, 2017
Rempex Pharmaceuticals — Earliest FDA Approval
- Aug 29, 2017
Rempex Pharmaceuticals — NDA Organization
- Aug 29, 2017
Rempex Pharmaceuticals — NDA Secondary Org
- Aug 29, 2017
The Medicines Company — NDA Secondary Org
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
2020s
- Jan 1, 2025
Earliest Phase 2 Sponsor(trial)
Indications
Approved for
Mechanism of action
BLKPC inhibitor
Combination products
vabomere
with meropenem
Also known as meropenem and vaborbactam
Approval history
- approvedPriority reviewFast trackAug 29, 2017
Chemistry & pharmacology
SMILES
O=C(O)C[C@@H]1CC[C@H](NC(=O)Cc2cccs2)B(O)O1- Mol. weight
- 297.14 g/mol
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
Oral
No
Parenteral
Yes
Topical
No
Sources
- ChEMBLCHEMBL3317857 ↗
- WikipediaVaborbactam ↗
- NCATS1C75676F8V ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06672978 | Phase 2 | Jan 31, 2025 | Department of Health and Human Services, Melinta Therapeutics |
| NCT03564158 | Phase 1 | May 1, 2018 | Department of Health and Human Services, Melinta Therapeutics |
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Department of Health and Human Services | Government | 2 | 0 | 2 | 2018 |
| Melinta Therapeutics | For profit | 2 | 2 | 2 | 2018 |
Marketing (4)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Rempex Pharmaceuticals | For profit | NDA | Aug 29, 2017 |
| Rempex Pharmaceuticals | For profit | SYN | Aug 29, 2017 |
| Rempex Pharmaceuticals | For profit | NDA2 | Aug 29, 2017 |
| The Medicines Company | For profit | NDA2 | Aug 29, 2017 |